| Yujie Zhao, MD PHD | |
|
509 W. University Ave., Urbana, IL 61801-1645 | |
| (217) 383-6636 | |
| (217) 383-3466 |
| Full Name | Yujie Zhao |
|---|---|
| Gender | Female |
| Speciality | Hematology/oncology |
| Experience | 30 Years |
| Location | 509 W. University Ave., Urbana, Illinois |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1316153034 | NPI | - | NPPES |
| 03383906 | Medicaid | NY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | 262915 (New York) | Secondary |
| 207RH0003X | Internal Medicine - Hematology & Oncology | 036138597 (Illinois) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mayo Clinic Florida | Jacksonville, FL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mayo Clinic - Florida | 5698689297 | 1310 |
News Archive
Aileron Therapeutics, a biopharmaceutical company leading the development of a new class of drugs called Stapled Peptides, announced today that its collaborators, James E. Bradner, MD of the Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT, and Gregory L. Verdine, PhD, Professor of Chemistry at Harvard University, published research in Nature entitled, "Direct Inhibition of the Notch Transcription Factor Complex." Results presented in the paper showed that Stapled Peptides can potently and directly inhibit the transcription factor Notch, an oncogene implicated in cancer cell proliferation and survival.
A new cancer treatment technology is one step closer to Salt Lake City. Today Huntsman Cancer Institute at the University of Utah announced a plan to add a proton therapy center to its Cancer Hospital.
A tool developed by researchers at Yale, Stanford, and Bioethics International can promote greater sharing of clinical trial data by pharmaceutical companies.
The team of Professor Burkhard Luy from KIT and Junior Professor Stefan F. Kirsch from the TUM has now shown for the first time that certain NMR parameters, the so-called residual dipolar couplings, can make a significant contribution towards determining the constitution of chemical compounds when traditional methods fail.
Arrowhead Research Corporation today announced that it has signed an option agreement with The University of Texas MD Anderson Cancer Center to negotiate a license in a defined field to a class of compounds that is believed to kill fat tissue by specifically targeting the blood vessels that supply it. The technology was developed in the laboratory of Drs. Renata Pasqualini and Wadih Arap at MD Anderson in Houston, Texas.
› Verified 7 days ago
| Entity Name | Mayo Clinic Jacksonville |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790772317 PECOS PAC ID: 5698689297 Enrollment ID: O20031118000388 |
News Archive
Aileron Therapeutics, a biopharmaceutical company leading the development of a new class of drugs called Stapled Peptides, announced today that its collaborators, James E. Bradner, MD of the Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT, and Gregory L. Verdine, PhD, Professor of Chemistry at Harvard University, published research in Nature entitled, "Direct Inhibition of the Notch Transcription Factor Complex." Results presented in the paper showed that Stapled Peptides can potently and directly inhibit the transcription factor Notch, an oncogene implicated in cancer cell proliferation and survival.
A new cancer treatment technology is one step closer to Salt Lake City. Today Huntsman Cancer Institute at the University of Utah announced a plan to add a proton therapy center to its Cancer Hospital.
A tool developed by researchers at Yale, Stanford, and Bioethics International can promote greater sharing of clinical trial data by pharmaceutical companies.
The team of Professor Burkhard Luy from KIT and Junior Professor Stefan F. Kirsch from the TUM has now shown for the first time that certain NMR parameters, the so-called residual dipolar couplings, can make a significant contribution towards determining the constitution of chemical compounds when traditional methods fail.
Arrowhead Research Corporation today announced that it has signed an option agreement with The University of Texas MD Anderson Cancer Center to negotiate a license in a defined field to a class of compounds that is believed to kill fat tissue by specifically targeting the blood vessels that supply it. The technology was developed in the laboratory of Drs. Renata Pasqualini and Wadih Arap at MD Anderson in Houston, Texas.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Yujie Zhao, MD PHD 611 W. Park St., Bwpc, Urbana, IL 61801-2500 Ph: (217) 383-6792 | Yujie Zhao, MD PHD 509 W. University Ave., Urbana, IL 61801-1645 Ph: (217) 383-6636 |
News Archive
Aileron Therapeutics, a biopharmaceutical company leading the development of a new class of drugs called Stapled Peptides, announced today that its collaborators, James E. Bradner, MD of the Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT, and Gregory L. Verdine, PhD, Professor of Chemistry at Harvard University, published research in Nature entitled, "Direct Inhibition of the Notch Transcription Factor Complex." Results presented in the paper showed that Stapled Peptides can potently and directly inhibit the transcription factor Notch, an oncogene implicated in cancer cell proliferation and survival.
A new cancer treatment technology is one step closer to Salt Lake City. Today Huntsman Cancer Institute at the University of Utah announced a plan to add a proton therapy center to its Cancer Hospital.
A tool developed by researchers at Yale, Stanford, and Bioethics International can promote greater sharing of clinical trial data by pharmaceutical companies.
The team of Professor Burkhard Luy from KIT and Junior Professor Stefan F. Kirsch from the TUM has now shown for the first time that certain NMR parameters, the so-called residual dipolar couplings, can make a significant contribution towards determining the constitution of chemical compounds when traditional methods fail.
Arrowhead Research Corporation today announced that it has signed an option agreement with The University of Texas MD Anderson Cancer Center to negotiate a license in a defined field to a class of compounds that is believed to kill fat tissue by specifically targeting the blood vessels that supply it. The technology was developed in the laboratory of Drs. Renata Pasqualini and Wadih Arap at MD Anderson in Houston, Texas.
› Verified 7 days ago
Joselyn Joseph, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 611 W. Park St., Hospitalist, Urbana, IL 61801 Phone: 217-383-3129 Fax: 217-326-1550 | |
Dr. Uday Bhaskar Kanakadandi, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 611 W Park St, Hvi, Urbana, IL 61801 Phone: 217-383-3110 | |
Dr. Nelson Onyekachukwu Okobia, Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 611 W Park St, Urbana, IL 61801 Phone: 217-549-6585 | |
Robert W. Kirby, M.D. Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 602 W University Ave, Urbana, IL 61801 Phone: 217-383-3311 | |
Pardeep Kumar Thourani, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 611 W Park St, Carle Forum, Ll, Urbana, IL 61801 Phone: 217-383-3110 | |
Benjamin J Rhee, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 611 W. Park St., Cardiology, Urbana, IL 61801 Phone: 217-904-7000 Fax: 217-904-7742 | |
Mr. Mobeen Zaka Haider, M.D. Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 611 W. Park St. Carle Foundation Hospital, Urbana, IL 61801 Phone: 217-383-3310 |